“Fredrik has received an attractive offer which was difficult to resist. Since Fredrik assumed the role as CEO of Enzymatica in 2015, the company has evolved in an impressive way and is well positioned for a continued international expansion. We are very grateful for Fredrik’s efforts and wish him all luck in his new position,” says Bengt Baron, Chairman of Enzymatica.
The information in this press release is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 14.00 CET on 21 December, 2019.
For more information, please contact:
Bengt Baron, Chairman, Enzymatica AB
Phone: +46 (0)708-59 30 09 | Email: email@example.com
Carl-Johan Wachtmeister, Communication manager Enzymatica AB
Phone: +46 (0)0701-88 50 21 | Email: firstname.lastname@example.org
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily
conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about ten markets. The strategy is to continue to grow by developing more health care products and strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases
Enzymatica’s certified adviser is Erik Penser Bank. Phone: +46 (0)8 463 83 00. Email: email@example.com
Enzymatica AB Ideon Science Park, SE-223 70 Lund, Sweden Telefon +46 46-286 31 00